☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Leo Pharma
LEO Pharma Reports the Regulatory Submission of Enstilar to the NMPA for Treating Plaque Psoriasis
September 27, 2024
LEO Pharma’s Anzupgo (Delgocitinib) Gains the CHMP’s Positive Opinion to Treat Moderate to Severe Chronic Hand Eczema (CHE)
July 26, 2024
LEO Pharma’s Adbry (tralokinumab-ldrm) Autoinjector Receives the US FDA’s Approval to Treat Moderate-to-Severe Atopic Dermatitis (...
June 13, 2024
Leo Pharma to Acquire Timber for ~$36M
August 22, 2023
PharmaShots Weekly Snapshots (February 06 - 10, 2023)
February 10, 2023
LEO Pharma Reports P-III Trial (DELTA 2) Results of Delgocitinib for Chronic Hand Eczema
February 10, 2023
Load more...
Back to Home
Modal title
×
Modal body text goes here.